The combination of withaferin A (0.2 µM) from Ashwagandha and sodium butyrate (2.5 mM), a gut microbiome metabolite, reduced viability in MCF-7, MDA-MB-231, and MDA-MB-157 breast cancer cell lines. The compounds targeted epigenetic machinery by decreasing DNA methyltransferase protein expression and inhibiting NFκB1 gene progression, while withaferin A also demonstrated histone deacetylase inhibition. This represents a compelling convergence of Ayurvedic medicine and microbiome research in oncology. The dual epigenetic approach—simultaneously targeting DNA methylation and histone modification—could offer advantages over single-agent therapies in reversing cancer-promoting gene silencing. The focus on triple-negative breast cancer is particularly relevant given its disproportionate impact on minority populations and limited treatment options. However, the study's limitations are significant: purely in vitro data provides no insight into bioavailability, tissue distribution, or real-world efficacy. The 72-hour treatment window is brief for assessing sustained epigenetic reprogramming. While mechanistically intriguing, this remains early-stage exploratory work requiring extensive preclinical validation before any clinical translation becomes viable.